Menu
Recruiting NCT06122584

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Phase III Interventional Prostate Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: [18F]PSMA-1007.
Who it may be relevant to
Registry conditions: Prostate Cancer. Basic parameters: from 18 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France, Germany, Italy, Japan, Netherlands +1
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Overview

This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Interventions

  • Drug [18F]PSMA-1007
    Diagnostic radiopharmaceutical for PET scan

Primary outcome measures

  • Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference [Time frame: 6 to 8 weeks post-surgery]

Eligibility criteria

Inclusion criteria

  • The patient (male) is aged 18 years or above.
  • The patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient AND has provided written informed consent to participate.
  • The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
  • The patient has at least high-risk disease as defined by the NCCN guidelines (version 1.2023). That is, the presence of any one or more of the following:
  • Overall ISUP grade group 4 or 5,
  • Clinical category T3a or greater,
  • Serum PSA level greater than 20 ng/ml.
  • The patient has undergone conventional imaging (CT or MRI, and bone scan if clinically indicated) to detect the presence of pelvic nodal involvement and bone or visceral metastases within 60 days of the planned PET-CT procedure.

Exclusion criteria

  • Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.
  • The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.
  • The patient has any contraindication(s) for and/or known hypersensitivity to any constituent(s) of \[18F\]PSMA-1007.
  • The patient is not able to have PET-CT scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan).
  • The patient is closely affiliated to the investigation site; e.g. is a first-degree relative of the investigator.
  • At the time of screening, the patient is receiving any other investigational agent(s), or he has received any such agent(s) within the previous 30 days, or he is scheduled to receive any such agent(s) in the period up to the planned date for the last study visit.
  • The patient has previously been enrolled in this trial.
  • The patient has previously undergone PET imaging with any PSMA-avid product.
  • The patient has histological evidence of small-cell carcinoma of the prostate.
  • The patient is clinically unstable or requires emergency treatment.
  • The patient has any mental condition rendering him incapable of understanding the nature, scope, and consequences of the trial as set out in the information given to the patient.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

Germany · 8 centers
  • Carl Gustav Carus Faculty of Medicine, TUD Dresden — Dresden
  • University Hospital Düsseldorf — Düsseldorf
  • St. Antonius Hospital — Gronau
  • University Hospital Hamburg-Eppendorf — Hamburg
  • University Hospital Leipzig — Leipzig
  • Klinikum rechts der Isar, TUM — München
  • University Hospital Münster — Münster
  • Universitätsmedizin Rostock — Rostock
Spain · 3 centers
  • Hospital Del Mar — Barcelona
  • Hospital Vall d'Hebron — Barcelona
  • Hospital Vithas Valencia 9 de Octubre — Valencia
Italy · 2 centers
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" — Meldola
  • IRCCS Ospedale Sacro Cuore-Don Calabria — Verona
Japan · 2 centers
  • The University of Osaka Hospital — Osaka
  • National Cancer Center — Tokyo
Netherlands · 2 centers
  • CWZ — Nijmegen
  • Radboud UMC — Nijmegen
France · 1 center
  • CHRU de Nancy — Nancy

Identifiers

NCT: NCT06122584 · EAGLE-i

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗